# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k091413   
B. Purpose for Submission: New devices   
C. Measurand: Cholesterol, HDL Cholesterol, and Triglyceride   
D. Type of Test: Quantitative, enzymatic photometric   
E. Applicant: Alfa Wasserman Diagnostic Technologies, LLC   
F. Proprietary and Established Names: S-Test Cholesterol (CHO) S-Test High Density Lipoprotein Cholesterol (HDL) S-Test Triglycerides (TG)

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.1175 - Cholesterol (total) test system 21 CFR 862.1475 - Lipoprotein test system 21 CFR 862.1705 Triglyceride test system

2. Classification: Class I, meet limitations of exemptions per 21 CFR 862.9 (c)(4) and (c)(9)

3. Product code:

CHH LBS CDT

4. Panel: 75 (clinical chemistry)

# H. Intended Use:

1. Intended use(s): Refer to indications for use below.

2. Indication(s) for use:

Cholesterol

The S-Test Cholesterol Reagent is intended for the quantitative determination of cholesterol concentration in serum or heparin plasma using the S40 Clinical Analyzer. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood, lipid and lipoprotein metabolism disorders. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

HDL Cholesterol

The S-Test High Density Lipoprotein Reagent is intended for the quantitative determination of HDL concentration in serum or heparin plasma using the S40 Clinical Analyzer. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

Triglyceride The S-Test Triglycerides Reagent is intended for the quantitative determination of triglyceride concentration in serum or heparin plasma using the S40

Clinical Analyzer. Triglyceride measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Alfa Wasserman Diagnostic Technologies S40 Clinical Analyzer

# I. Device Description:

All three reagents are provided in a ready-to-use cartridge with a barcode to automatically identify the reagent to the S40 clinical analyzer. Each cartridge has a separate reservoir for reagent 1 and reagent 2, a reaction cell, and a photometric cuvette.

The S-Test Cholesterol (CHO) Reagent Cartridge has the following components: Component Quantity

CHO Reagent (1) 4-aminoantipyrine Cholesterol oxidase Peroxidase (Horseradish)

1.6 mmol/L $> 0 . 2 \ \mathrm { U / m L }$ $> 1 . 6 \mathrm { U / m L }$

CHO Reagent (2) Cholesterol oxidase 2 U/mL N-ethyl-N-sulfobutyl-m-toluidine disodium salt 1.5 mmol/L

The S-Test High Density Lipoprotein (HDL) Reagent Cartridge has the following components:

# Component

Quantity

0.5 mmol/L   
1.0 U/mL

HDL Reagent (1)   
N, N-bis (4-sulfobutyl)-m-toluidine disodium salt (DSBmT)   
Cholesterol oxidase   
Bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane   
(Bis-Tris) $\left( \mathrm { p H } 6 . 0 \right)$   
Peroxidase (Horseradish)

50 mmol/L < 1.3 ppg U/mL

1.0 mmol/L $< 2 \%$

HDL Reagent (2)   
4-aminoantipyrine   
Surface-active agent   
Bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane   
(Bis-Tris) $\left( \mathrm { p H } 6 . 0 \right)$   
Cholesterol oxidase

50 mmol/L $\geq 1 . 0 \mathrm { U / m L }$

The S-Test Triglycerides (TG) Reagent Cartridge has the following components: Component Quantity

TG Reagent (1)   
Glycerol kinase   
Glycerol-3-phosphate oxidase   
N-ethyl-N-sulfobutyl-m-toluidine disodium salt   
Piperazine-N-N’-bis (2-ethanesulfonic acid (PIPES)   
buffer $\mathrm { ( p H } 7 . 0 )$

1.5 U/mL   
2 U/mL   
1.5 mmol/L

100 mmol/L

TG Reagent (2)   
4-aminoantipyrine   
Lipoprotein lipase   
Peroxidase (Horseradish)   
Piperazine-N-N’-bis (2-ethanesulfonic acid (PIPES)   
buffer $\mathrm { ( p H } 6 . 5 )$

2.5 mmol/L > 1 U/mL $> 5 \ \mathrm { U / m L }$

50 mmol/L

# J. Substantial Equivalence Information:

1. Predicate device name(s): Alfa Wassermann Ace CHOLESTEROL Reagent Alfa Wassermann Ace HDL-C (HDLNEW) Reagent Alfa Wassermann Ace TRIGLYCERIDES Reagent

2. Predicate 510(k) number: k931786

3. Comparison with predicate: Cholesterol

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Intended for the quantitativedetermination of total cholesterol.</td></tr><tr><td colspan="1" rowspan="1">Cholesterol ReferenceMethod LaboratoryNetwork (CRMLN)certification</td><td colspan="1" rowspan="1">Not certified</td><td colspan="1" rowspan="1">Not certified</td></tr><tr><td colspan="1" rowspan="1">Principle</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Enzymatic (cholesterolesterase/cholesterol oxidase)</td></tr><tr><td colspan="1" rowspan="1">Intended Sites</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Clinical laboratories or physicianoffice labs</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Instrument Platform(s)</td><td rowspan=1 colspan=1>S40 Clinical Analyzer</td><td rowspan=1 colspan=1>ACE and NExCTClinical ChemistrySystems</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Each lot is calibrated bythe manufacturer prior toshipment using materialtraceable to NISTStandard ReferenceMaterial 911</td><td rowspan=1 colspan=1>Calibrated by referencingthe change in absorbanceof the unknown samplesto the change inabsorbance of thestandard; the use ofGEMCAL ReferenceSerum is recommended</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Serum or Heparin Plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>10 μL</td><td rowspan=1 colspan=1>3 μL</td></tr><tr><td rowspan=1 colspan=1>Detection Limit</td><td rowspan=1 colspan=1>7 mg/dL</td><td rowspan=1 colspan=1>2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Linearity Range</td><td rowspan=1 colspan=1>7 - 370 mg/dL</td><td rowspan=1 colspan=1>2 - 600 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Detection Wavelength</td><td rowspan=1 colspan=1>600/800 nm</td><td rowspan=1 colspan=1>505/647 nm</td></tr></table>

HDL Cholesterol   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Intended for thequantitativedetermination of HDLcholesterol.</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Each lot is calibrated bythe manufacturer prior toshipment using materialtraceable toHECTEF (StandardReference CenterFoundation, Ltd.)JCCRM223. The 2-Dbarcode printed on eachcartridge provides theanalyzer with lot-specificcalibration data.</td><td rowspan=1 colspan=1>Calibrated by referencingthe change in absorbanceof the unknown samplesto the change inabsorbance of thestandard; the use ofGEMCAL ReferenceSerum is recommended.</td></tr><tr><td rowspan=1 colspan=1>Cholesterol ReferenceMethod LaboratoryNetwork (CRMLN)certification</td><td rowspan=1 colspan=1>Not certified</td><td rowspan=1 colspan=1>Not certified</td></tr><tr><td rowspan=1 colspan=1>Principle</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Detergent solubilizationof HDL to selectivelymeasure HDL cholesterolusing an enzymaticmethod</td></tr><tr><td rowspan=1 colspan=1>Intended Sites</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Clinical laboratories orphysician office labs</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Instrument Platform(s)</td><td colspan="1" rowspan="1">S40 Clinical Analyzer</td><td colspan="1" rowspan="1">ACE and NExCTClinical ChemistrySystems</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Each lot is calibrated bythe manufacturer prior toshipment using materialtraceable to ReferenceMaterial Institute forClinical ChemistryStandards JCCRM223</td><td colspan="1" rowspan="1">Calibrated by referencingthe change in absorbanceof the unknown samplesto the change inabsorbance of thestandard; the use ofGEMCAL ReferenceSerum is recommended</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Serum or Heparin Plasma</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">5 μL</td><td colspan="1" rowspan="1">3 μL</td></tr><tr><td colspan="1" rowspan="1">Detection Limit</td><td colspan="1" rowspan="1">6 mg/dL</td><td colspan="1" rowspan="1">4 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Linearity Range</td><td colspan="1" rowspan="1">14 - 125 mg/dL</td><td colspan="1" rowspan="1">4 - 125 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Detection Wavelength</td><td colspan="1" rowspan="1">600/700 nm</td><td colspan="1" rowspan="1">592/692 nm</td></tr></table>

Triglyceride   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Intended for the quantitativedetermination of triglyceride.</td></tr><tr><td rowspan=1 colspan=1>Principle</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Coupled enzymatic reaction that useslipase, glycerol kinase, glycerol-3-phosphate oxidase and peroxidaseenzymes to form a colored pigment</td></tr><tr><td rowspan=1 colspan=1>Intended Sites</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Clinical laboratories or physician officelabs</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Instrument Platform(s)</td><td rowspan=1 colspan=1>S40 Clinical Analyzer</td><td rowspan=1 colspan=1>ACE, ACE Alera, andNExCT ClinicalChemistry Systems</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Each lot is calibrated bythe manufacturer prior toshipment using materialtraceable to ReferenceMaterial Institute forClinical ChemistryStandards JCCRM223</td><td rowspan=1 colspan=1>Calibrated byreferencing the change inabsorbance of theunknown samples to thechange in absorbance ofthe standard; the use ofGEMCAL ReferenceSerum is recommended</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Serum or Heparin Plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>5 μL</td><td rowspan=1 colspan=1>3 μL</td></tr><tr><td rowspan=1 colspan=1>Detection Limit</td><td rowspan=1 colspan=1>12 mg/dL</td><td rowspan=1 colspan=1>6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Linearity Range</td><td rowspan=1 colspan=1>15 - 746 mg/dL</td><td rowspan=1 colspan=1>6 - 1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Detection Wavelength</td><td rowspan=1 colspan=1>600/800 nm</td><td rowspan=1 colspan=1>505/692 nm</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline

CLSI EP7-A2: Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition

CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline - Second Edition

CLSI EP10-A3: Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline - Third Edition

CLSI EP9-A2: Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline - Second Edition

CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline

# L. Test Principle:

# Cholesterol

The cholesterol in the sample is classified into cholesterol esters and free cholesterol. The cholesterol esters become free cholesterol through the action of cholesterol esterase (CE).

The free cholesterol is oxidized by cholesterol oxidase (COD) to produce hydrogen peroxide, esters and free cholesterol. The cholesterol esters become free cholesterol through the action of cholesterol esterase (CE).

The hydrogen peroxide oxidizes and condenses 4-aminoaminoantipyrine and N-ethyl-N-sulfobutyl-m-toluidine (ESBmT) under the influence of peroxidase (POD) to produce a reddish-purple pigment.

Total cholesterol concentration is determined by measuring the absorbance of this reddish-purple pigment. The difference in absorbance, monitored bichromatically at $6 0 0 \mathrm { n m } / 8 0 0 \mathrm { n m }$ is directly proportional to the cholesterol concentration in the sample.

# HDL Cholesterol

By using a special surface-active agent that preferentially solubilizes HDL and not other lipoproteins (LDL, VLDL, and chylomicrons), the HDL cholesterol is measured via a quickly initiated enzymatic reaction. Therefore, only HDL cholesterol is specifically measured.

The hydrogen peroxide oxidizes and condenses 4-aminoaminoantipyrine and N,N'-bis(4-sulfobutyl)-m-toluidine disodium salt (DSBmT) in the presence of peroxidase (POD) to produce a reddish-purple pigment.

HDL cholesterol concentration is determined by measuring the absorbance of this reddish-purple pigment. The difference in absorbance, monitored bichromatically at $6 0 0 \mathrm { n m } / 7 0 0 \mathrm { n m }$ is directly proportional to the HDL concentration in the sample.

# Triglyceride

Free glycerol in the sample is converted to glycerol-3-phosphoric acid through the action of glycerol kinase (GK) and the adenosine triphosphate (ATP) substrate. Glycerol-3-phosphoric acid is converted to hydrogen peroxide via the action of glycerol-3-phosphate oxidase (GPO); peroxide is then decomposed into water and oxygen via the action of catalase.

The neutral fat in the sample is quickly hydrolyzed into glycerol and fatty acid by the lipoprotein lipase (LPL) contained in the second reagent.

The glycerol product is converted to glycerol-3-phosphoric acid via the action of GK and the ATP substrate which in turn produces hydrogen peroxide via the action of GPO. The hydrogen peroxide oxidizes/condenses 4- aminoantipyrine and N-ethyl-N-sulfobutyl-m-toluidine (ESBmT), via the action of peroxidase (POD) to produce a reddish purple pigment. The original neutral fat concentration (triglyceride) is determined by measuring the absorbance of the reddish purple pigment produced.

The difference in absorbance between the final reading and the blank, monitored bichromatically at $6 0 0 \mathrm { n m } / 8 0 0 \mathrm { n m }$ , is directly proportional to the triglyceride concentration in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Cholesterol

Precision studies were conducted in house on serum samples at three concentrations over 22 days. Results were as follows:

<table><tr><td rowspan=1 colspan=1>Sample 1 (92 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation (mg/dL)</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation (%)</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.5</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2 (171 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation(mg/dL)</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation (%)</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.2</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 3 (263 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation (mg/dL)</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation (%)</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.6</td></tr></table>

Precision studies were also conducted in three Physician Office Laboratory (POL) sites on serum samples at three concentrations over five days. Results were as follows:

HDL Cholesterol   

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>SD (mg/dL) or % CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>107</td><td rowspan=1 colspan=1>SD 1.0</td><td rowspan=1 colspan=1>SD 1.0</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>107</td><td rowspan=1 colspan=1>SD 0.7</td><td rowspan=1 colspan=1>SD 0.7</td></tr><tr><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.7%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>106</td><td rowspan=1 colspan=1>SD 0.9</td><td rowspan=1 colspan=1>SD 1.1</td></tr><tr><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>184</td><td rowspan=1 colspan=1>SD 1.1</td><td rowspan=1 colspan=1>SD 1.4</td></tr><tr><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>185</td><td rowspan=1 colspan=1>SD 1.8</td><td rowspan=1 colspan=1>SD 1.8</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>182</td><td rowspan=1 colspan=1>SD 1.1</td><td rowspan=1 colspan=1>SD 1.3</td></tr><tr><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.7%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>287</td><td rowspan=1 colspan=1>SD 2.2</td><td rowspan=1 colspan=1>SD 2.9</td></tr><tr><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>292</td><td rowspan=1 colspan=1>SD 0.9</td><td rowspan=1 colspan=1>SD 2.3</td></tr><tr><td rowspan=1 colspan=1>0.3%</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>288</td><td rowspan=1 colspan=1>SD 1.4</td><td rowspan=1 colspan=1>SD 2.0</td></tr><tr><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.7%</td></tr></table>

Precision studies were conducted in house on serum samples at three concentrations over 22 days. Results were as follows:

<table><tr><td rowspan=1 colspan=1>Sample 1 (24 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation (mg/dL)</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation (%)</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>6.5</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2 (75 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation (mg/dL)</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation (%)</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>6.0</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 3 (94 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation (mg/dL)</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation (%)</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>6.1</td></tr></table>

Precision studies were also conducted in three Physician Office Laboratory (POL) sites on serum samples at three concentrations over five days. Results were as follows:

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>SD (mg/dL) or % CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>22</td><td rowspan=1 colspan=1>SD 0.3</td><td rowspan=1 colspan=1>SD 0.3</td></tr><tr><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>22</td><td rowspan=1 colspan=1>SD 0.6</td><td rowspan=1 colspan=1>SD 0.6</td></tr><tr><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>22</td><td rowspan=1 colspan=1>SD 0.5</td><td rowspan=1 colspan=1>SD 0.6</td></tr><tr><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.7%</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>SD (mg/dL) or % CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Within-Run</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>58</td><td rowspan=1 colspan=1>SD 0.9</td><td rowspan=1 colspan=1>SD 1.0</td></tr><tr><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>57</td><td rowspan=1 colspan=1>SD 0.8</td><td rowspan=1 colspan=1>SD 0.8</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.4%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>58</td><td rowspan=1 colspan=1>SD 1.2</td><td rowspan=1 colspan=1>SD 1.2</td></tr><tr><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>111</td><td rowspan=1 colspan=1>SD 2.4</td><td rowspan=1 colspan=1>SD 2.8</td></tr><tr><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>110</td><td rowspan=1 colspan=1>SD 1.5</td><td rowspan=1 colspan=1>SD 1.9</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>113</td><td rowspan=1 colspan=1>SD 2.5</td><td rowspan=1 colspan=1>SD 2.5</td></tr><tr><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.3%</td></tr></table>

Triglyceride

Precision studies were conducted in house on serum samples at three concentrations over 22 days. Results were as follows:

<table><tr><td rowspan=1 colspan=1>Sample 1 (97 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation (mg/dL)</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation (%)</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>4.3</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2 (130 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation (mg/dL)</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.5</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation (%)</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>4.3</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 3 (206 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation (mg/dL)</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>7.7</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation (%)</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.8</td></tr></table>

An additional precision study was conducted in-house using a sample with an elevated triglyceride concentration. A total of 50 replicates were analyzed over 5 days on each of three analyzers Results combining data from all three analyzers were as follows:

<table><tr><td rowspan=1 colspan=1>Sample 4 675 mg/dL)</td><td rowspan=1 colspan=1>Within Run</td><td rowspan=1 colspan=1>Between Run</td><td rowspan=1 colspan=1>Between Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, (mg/dL)</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>10.1</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation (%)</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.5</td></tr></table>

Precision studies were also conducted in three Physician Office Laboratory (POL) sites on serum samples at three concentrations over five days. Results were as follows:

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>SD (mg/dL) or % CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>73</td><td rowspan=1 colspan=1>SD 2.5</td><td rowspan=1 colspan=1>SD 2.5</td></tr><tr><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>74</td><td rowspan=1 colspan=1>SD 2.8</td><td rowspan=1 colspan=1>SD 2.8</td></tr><tr><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>73</td><td rowspan=1 colspan=1>SD 2.8</td><td rowspan=1 colspan=1>SD 2.8</td></tr><tr><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>125</td><td rowspan=1 colspan=1>SD 1.6</td><td rowspan=1 colspan=1>SD 1.6</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>127</td><td rowspan=1 colspan=1>SD 3.6</td><td rowspan=1 colspan=1>SD 3.6</td></tr><tr><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>2.8%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>124</td><td rowspan=1 colspan=1>SD 2.4</td><td rowspan=1 colspan=1>SD 2.4</td></tr><tr><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>202</td><td rowspan=1 colspan=1>SD 4.6</td><td rowspan=1 colspan=1>SD 4.6</td></tr><tr><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.3%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>203</td><td rowspan=1 colspan=1>SD 4.0</td><td rowspan=1 colspan=1>SD 4.4</td></tr><tr><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>202</td><td rowspan=1 colspan=1>SD 6.1</td><td rowspan=1 colspan=1>SD 6.1</td></tr><tr><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>3.0%</td></tr></table>

# b. Linearity/assay reportable range:

Commercial linearity standards were assayed to test that results obtained across the measuring range were linear. The mean value of each set of quadruplicate determinations was determined.

Cholesterol

Percent recoveries ranged from $9 8 \% - 1 0 0 \%$ when testing samples from 2 – $3 7 0 \mathrm { m g / d L }$ . The linear regression equation obtained for the study was $\mathbf { y } =$ 1.005x – 3.00, $\mathrm { r } ^ { 2 } = 0 . 9 9 9 \bar { 5 }$ . The claimed measuring range is $7 - 3 7 0 \mathrm { m g / d L }$ .

HDL Cholesterol

Percent recoveries ranged from $1 0 0 \% - 1 0 3 \%$ when testing samples from $1 4 -$ $1 4 0 \mathrm { m g / d L }$ . The linear regression equation obtained for the study was $\mathbf { y } =$ $1 . 0 0 2 \mathrm { x } + 0 . 7 0$ , $\mathrm { r } ^ { 2 } = 0 . 9 9 9 \dot { 3 }$ . The claimed measuring range is $1 4 - 1 2 5 \mathrm { m g / d L }$ .

Triglyceride

Percent recoveries ranged from $9 5 \% - 1 0 0 \%$ when testing samples from 13 – $7 4 6 ~ \mathrm { m g / d L }$ . The linear regression equation obtained for the study was $\mathbf { y } =$

1.005x – 4.92, $\mathrm { r } ^ { 2 } = 0 . 9 9 9 6$ . The claimed measuring range is $1 5 - 7 4 6 \ \mathrm { m g / d L }$ c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Cholesterol - Each lot is calibrated by the manufacturer prior to shipment using material traceable to NIST Standard Reference Material 911.

HDL Cholesterol and Triglyceride - Each lot is calibrated by the manufacturer prior to shipment using material traceable to Reference Material Institute for Clinical Chemistry Standards JCCRM223

The 2-D barcode printed on each cartridge provides the S-40 Clinical Analyzer with lot-specific calibration data.

These methods for cholesterol, HDL cholesterol, and triglyceride have not been tested or certified by the Cholesterol Reference Method Laboratory Network (CRMLN). This information about the CRMLN certification is stated in the labeling.

# d. Detection limit:

The limit of detection was determined by assaying five low samples (serum samples) and five true blanks (human serum albumin in saline). Testing was carried out over three days on two S40 Clinical Analyzers. Serum samples and true blanks were assayed every day for a total of 60 measurements. The limit of detection was determined to be $7 \mathrm { m g / d L }$ for cholesterol, $6 \mathrm { m g / d L }$ for HDL cholesterol, and $1 2 \mathrm { m g / d L }$ for triglyceride.

# e. Analytical specificity:

The sponsor investigated the possibility of interference from ascorbic acid, unconjugated bilirubin, hemolysis, and lipemia. The concentrations of samples tested are presented in the table below.

Cholesterol   

<table><tr><td colspan="1" rowspan="1">Potential InterferentConcentrations Tested (mg/dL)</td><td colspan="1" rowspan="1">Low CholesterolConcentrationTested(mg/dL)</td><td colspan="1" rowspan="1">HighCholesterolConcentrationTested (mg/dL)</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid @1.6, 3.1, 6.3, 12.5, 25, 50</td><td colspan="1" rowspan="1">53</td><td colspan="1" rowspan="1">296</td></tr><tr><td colspan="1" rowspan="1">Unconjugated Bilirubin @1.6, 3.1, 6.3, 2.5, 25, 50</td><td colspan="1" rowspan="1">187</td><td colspan="1" rowspan="1">270</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin@31.3, 62.5, 125, 250, 500, 1000</td><td colspan="1" rowspan="1">170</td><td colspan="1" rowspan="1">255</td></tr><tr><td>Lipemia (Intralipid) @ 62.5, 125, 250, 500, 1000, 2000</td><td>169</td><td>251</td></tr></table>

HDL Cholesterol   

<table><tr><td rowspan=1 colspan=1>Potential InterferentConcentrations Tested (mg/dL)</td><td rowspan=1 colspan=1>Low HDLCholesterolConcentrationTested(mg/dL)</td><td rowspan=1 colspan=1>High HDLCholesterolConcentrationTested(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid@1.6, 3.1, 6.3, 12.5, 25, 50</td><td rowspan=1 colspan=1>15.3</td><td rowspan=1 colspan=1>48.7</td></tr><tr><td rowspan=1 colspan=1>UnconjugatedBilirubin@1.6, 3.1, 6.3, 22.5, 25, 50</td><td rowspan=1 colspan=1>21.3</td><td rowspan=1 colspan=1>61.7</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin@31.3, 62.5, 125, 250, 500, 1000</td><td rowspan=1 colspan=1>20.3</td><td rowspan=1 colspan=1>56.3</td></tr><tr><td rowspan=1 colspan=1>Triglyceridefrom 94  866mg/dL</td><td rowspan=1 colspan=1>30.0</td><td rowspan=1 colspan=1>83.3</td></tr></table>

Triglyceride   

<table><tr><td rowspan=1 colspan=1>Potential InterferentConcentrations Tested (mg/dL)</td><td rowspan=1 colspan=1>Low TriglycerideConcentrationTested(mg/dL)</td><td rowspan=1 colspan=1>HighTriglycerideConcentrationTested(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid @1.6, 3.1, 6.3, 12.5, 25, 50</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>230</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin @1.6, 3.1, 6.3, 2.5, 25, 50</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>297</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin@31.3, 62.5, 125, 250, 500, 1000</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>274</td></tr></table>

The sponsor defined interference as a change greater than $10 \%$ or the lowest reportable concentration of the assay. Based on these criteria, the sponsor states the following in the package inserts:

# Cholesterol:

No significant interference from ascorbic acid, unconjugated bilirubin, hemolysis, or lipemia.

# HDL Cholesterol:

Ascorbic Acid: No significant interference below $2 5 \mathrm { m g / d L }$ . Ascorbic acid concentrations greater than $2 5 \mathrm { m g / d L }$ may cause interference. Negative interference $( > 1 0 \% )$ occurred at $5 0 \mathrm { m g / d L }$ .

Unconjugated Bilirubin: No significant interference.

Hemolysis: No significant interference below $5 0 0 \mathrm { m g / d L }$ . Hemoglobin concentrations greater than $5 0 0 \mathrm { m g / d L }$ may cause may cause interference. Negative interference $( \sim 1 1 \% )$ occurred at $1 0 0 0 \mathrm { m g / d L }$ . The labeling states that clear unhemolyzed samples should be used.

Triglyceride: No significant interference below $8 6 6 ~ \mathrm { m g / d L }$ .

Triglyceride:

No significant interference from ascorbic acid, unconjugated bilirubin, or hemolysis.

f. Assay cut-off:

Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

Cholesterol

A series of 98 serum specimens with cholesterol values ranging from 31 to $3 3 5 \mathrm { m g / d L }$ were assayed in-house on the S40 Clinical Analyzer using the STest Cholesterol Reagent and on the Ace Clinical Chemistry System using the predicate device. Least-squares regression analysis yielded the following results:

<table><tr><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>Y = 0.978x + 3.5</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.9832</td></tr><tr><td rowspan=1 colspan=1>Std. Error Est.</td><td rowspan=1 colspan=1>11.3</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Slope</td><td rowspan=1 colspan=1>0.942 to 1.014</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Intercept</td><td rowspan=1 colspan=1>-3.8 to 10.8</td></tr></table>

Additional method comparison studies were performed at three Physician Office Laboratories (POLs). Operators assayed serum samples ranging from $1 8 - 3 3 4 \mathrm { m g / d L }$ on the S40 Clinical Analyzer and the ACE Clinical Chemistry System. The following linear regression data was obtained using Deming analysis:

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceIntervalSlope</td><td rowspan=1 colspan=1>ConfidenceIntervalIntercept</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>53-315</td><td rowspan=1 colspan=1>y = 0.944x + 0.3</td><td rowspan=1 colspan=1>0.9585</td><td rowspan=1 colspan=1>16.7</td><td rowspan=1 colspan=1>0.868 to 1.021</td><td rowspan=1 colspan=1>-15.7 to 16.2</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>18-328</td><td rowspan=1 colspan=1>y = 1.016x + 2.5</td><td rowspan=1 colspan=1>0.9969</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.995 to 1.037</td><td rowspan=1 colspan=1>-1.9 to 6.8</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>19-334</td><td rowspan=1 colspan=1>y = 1.031x + 2.9</td><td rowspan=1 colspan=1>0.9958</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>1.007 to 1.056</td><td rowspan=1 colspan=1>-2.5 to 8.3</td></tr></table>

# HDL Cholesterol

A series of 94 serum specimens with HDL Cholesterol values ranging from 15 to $1 1 6 \mathrm { m g / d L }$ were assayed on the S40 Clinical Analyzer using the S-Test HDL Reagent and on the Ace Clinical Chemistry System using the predicate device. Least-squares regression analysis yielded the following results:

<table><tr><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>Y = 0.972x + 2.4</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.9696</td></tr><tr><td rowspan=1 colspan=1>Std. Error Est.</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Slope</td><td rowspan=1 colspan=1>0.923 to 1.022</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Intercept</td><td rowspan=1 colspan=1>-0.5 to 5.2</td></tr></table>

Additional method comparison studies were performed at three Physician Office Laboratories (POLs). Operators assayed serum samples ranging from $1 7 - 1 0 7 \mathrm { m g / d L }$ on the S40 Clinical Analyzer and the ACE Clinical Chemistry System. The following linear regression data was obtained using Deming analysis:

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceIntervalSlope</td><td rowspan=1 colspan=1>ConfidenceIntervalIntercept</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>17-107</td><td rowspan=1 colspan=1>y = 0.949x+5.2</td><td rowspan=1 colspan=1>0.9696</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.879 to1.018</td><td rowspan=1 colspan=1>1.4 to 9.0</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>17-101</td><td rowspan=1 colspan=1>y = 0.985x+1.3</td><td rowspan=1 colspan=1>0.9915</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.950 to1.020</td><td rowspan=1 colspan=1>-0.7 to 3.2</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>17-98</td><td rowspan=1 colspan=1>y = 0.957x+1.8</td><td rowspan=1 colspan=1>0.9957</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.933 to0.981</td><td rowspan=1 colspan=1>0.4 to 3.1</td></tr></table>

Triglyceride

A series of 87 serum specimens with Triglyceride values ranging from 24 to $5 8 4 ~ \mathrm { m g / d L }$ were assayed in-house on the S40 Clinical Analyzer using the STest Triglyceride Reagent and on the Ace Clinical Chemistry System using the predicate device. Least-squares regression analysis yielded the following results:

<table><tr><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>Y = 1.068x - 17.5</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.9965</td></tr><tr><td rowspan=1 colspan=1>Std. Error Est.</td><td rowspan=1 colspan=1>8.7</td></tr><tr><td rowspan=1 colspan=1>ConfidenceInterval Slope</td><td rowspan=1 colspan=1>1.049 to 1.088</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Intercept</td><td rowspan=1 colspan=1>-21.2 to -13.7</td></tr></table>

Additional method comparison studies were performed at three Physician Office Laboratories (POLs). Operators assayed serum samples ranging from $1 5 - 7 3 3 \mathrm { m g / d L }$ on the S40 Clinical Analyzer and the ACE Clinical Chemistry System. The following linear regression data was obtained using Deming analysis:

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceInterval Slope</td><td rowspan=1 colspan=1>ConfidenceInterval Intercept</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>15-627</td><td rowspan=1 colspan=1>y = 0.966x -14.0</td><td rowspan=1 colspan=1>0.9958</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>0.940 to 0.993</td><td rowspan=1 colspan=1>-19.0 to -9.0</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>17-733</td><td rowspan=1 colspan=1>y = 1.038x -2.7</td><td rowspan=1 colspan=1>0.9990</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>1.024 to 1.051</td><td rowspan=1 colspan=1>-5.8 to 0.5</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>19-707</td><td rowspan=1 colspan=1>y = 1.057x -2.9</td><td rowspan=1 colspan=1>0.9963</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>1.030 to 1.084</td><td rowspan=1 colspan=1>-8.7 to 2.9</td></tr></table>

b. Matrix comparison:

Cholesterol

A study was performed by comparing cholesterol concentrations on 29 paired samples drawn from the same patients in serum and lithium heparin plasma tubes at a clinical laboratory. All specimens were assayed on the S40 Clinical Analyzer using the S-Test cholesterol reagent. The serum results ranged from 22 to $2 4 9 \mathrm { m g / d L }$ . Least-square regression analysis yielded the following results:

<table><tr><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>y= 1.015x -4.1</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.9968</td></tr><tr><td rowspan=1 colspan=1>Std. Error Est.</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Slope</td><td rowspan=1 colspan=1>0.982 to 1.047</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Intercept</td><td rowspan=1 colspan=1>-9.1 to 1.0</td></tr></table>

HDL Cholesterol

A study was performed by comparing HDL cholesterol concentrations on 36 paired samples drawn from the same patients in serum and lithium heparin plasma tubes at a clinical laboratory. All specimens were assayed on the S40 Clinical Analyzer using the S-Test HDL cholesterol reagent. The serum results ranged from 14 to $1 2 4 \mathrm { m g / d L }$ . Least-square regression analysis yielded the following results:

<table><tr><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>y = 1.020x - 1.1</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.9890</td></tr><tr><td rowspan=1 colspan=1>Std. Error Est.</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Slope</td><td rowspan=1 colspan=1>0.967 to 1.073</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Intercept</td><td rowspan=1 colspan=1>-3.6 to 1.5</td></tr></table>

Triglyceride

A study was performed by comparing HDL triglyceride concentrations on 30 paired samples drawn from the same patients in serum and lithium heparin plasma tubes at a clinical laboratory. All specimens were assayed on the S40 Clinical Analyzer using the S-Test HDL triglyceride reagent. The serum results ranged from 36 to $5 7 2 \mathrm { m g / d L }$ . Least-square regression analysis yielded the following results:

<table><tr><td rowspan=1 colspan=1>Regression Equation</td><td rowspan=1 colspan=1>y = 0.957x + 0.0</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.9849</td></tr><tr><td rowspan=1 colspan=1>Std. Error Est.</td><td rowspan=1 colspan=1>24.0</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Slope</td><td rowspan=1 colspan=1>0.892 to 1.021</td></tr><tr><td rowspan=1 colspan=1>Confidence Interval Intercept</td><td rowspan=1 colspan=1>-16.4 to 16.5</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off: Not applicable. Clinical studies are not typically submitted for this device type.

5. Expected values/Reference range:

Reference ranges are taken from the Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III); Executive Summary, 2002.

<table><tr><td rowspan=1 colspan=2>Total Cholesterol (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>&lt; 200</td><td rowspan=1 colspan=1>Desirable</td></tr><tr><td rowspan=1 colspan=1>200 -239</td><td rowspan=1 colspan=1>Borderline</td></tr><tr><td rowspan=1 colspan=1>≥ 240</td><td rowspan=1 colspan=1>High</td></tr></table>

<table><tr><td rowspan=1 colspan=2>HDL Cholesterol (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>&lt; 40</td><td rowspan=1 colspan=1>Low</td></tr><tr><td rowspan=1 colspan=1>≥ 60</td><td rowspan=1 colspan=1>High</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Triglyceride (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>&lt; 150</td><td rowspan=1 colspan=1>Normal</td></tr><tr><td rowspan=1 colspan=1>150 - 199</td><td rowspan=1 colspan=1>Borderline High</td></tr><tr><td rowspan=1 colspan=1>200  499</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>≥ 500</td><td rowspan=1 colspan=1>Very High</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.